Search Results - "Falchook G"

Merkel cell polyomavirus and human papilloma virus in proliferative skin lesions arising in patients treated with BRAF inhibitors.

Authors: Falchook, G. Rady, P. Konopinski, J. et al.

Source: Archives of Dermatological Research. Jul2016, Vol. 308 Issue 5, p357-365. 9p.

Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer†.

Authors: Falchook, G. S. Moulder, S. L. Wheler, J. J. et al.

Source: Annals of Oncology. Dec2013, Vol. 24 Issue 12, p3004-3011. 8p.

Aberrations in the epidermal growth factor receptor gene in 958 patients with diverse advanced tumors: implications for therapy.

Authors: Wheler, J. J. Falchook, G. S. Tsimberidou, A. M. et al.

Source: Annals of Oncology. Mar2013, Vol. 24 Issue 3, p838-842. 5p. 2 Charts.

Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies.

Authors: Falchook, G. Duvic, M. Hong, D. et al.

Source: Cancer Chemotherapy & Pharmacology. May2012, Vol. 69 Issue 5, p1117-1126. 10p.

Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment.

Authors: Falchook, G. S. Vega, F. Dang, N. H. et al.

Source: Annals of Oncology. Jun2009, Vol. 20 Issue 6, p1080-1085. 6p. 1 Color Photograph, 4 Charts, 1 Graph.

Phase 1/2 study of weekly paclitaxel with or without alisertib, an investigational aurora a kinase inhibitor: Phase 1 results in patients with recurrent epithelial ovarian, fallopian tube, primary peritoneal, or breast cancer

Authors: Falchook, G. Goff, B. Kurzrock, R. et al.

Source: Gynecologic Oncology. Mar2012 Supplement, Vol. 125, pS31-S32. 0p.

Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes.

Authors: Henary, H. Hong, D. S. Falchook, G. S. et al.

Source: Annals of Oncology. Aug2013, Vol. 24 Issue 8, p2158-2165. 8p. 3 Charts, 2 Graphs.

Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer.

Authors: Strickler, J. H. Satake, H. George, T. J. et al.

Source: New England Journal of Medicine. 1/5/2023, Vol. 388 Issue 1, p33-43. 11p.

Sotorasib for Lung Cancers with p.G12C Mutation.

Authors: Skoulidis, F. Li, B. T. Dy, G. K. et al.

Source: New England Journal of Medicine. 6/24/2021, Vol. 384 Issue 25, p2371-2381. 11p.

KRAS^G12C Inhibition with Sotorasib in Advanced Solid Tumors.

Authors: Hong, D. S. Fakih, M. G. Strickler, J. H. et al.

Source: New England Journal of Medicine. 9/24/2020, Vol. 383 Issue 13, p1207-1217. 11p.

73PCemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort (EC) in a phase I study.

Authors: He, A R Weiss, G J Falchook, G et al.

Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.

1145PResponses and durability of clinical benefit in triple negative breast cancer patients treated with pegilodecakin monotherapy or in combination with platinum plus taxane-based chemotherapy.

Authors: Naing, A Autio, K A Falchook, G S et al.

Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p. 1 Chart.

1143PResponses and durability of clinical benefit in pancreatic ductal adenocarcinoma (PDAC) patients treated with pegilodecakin (AM0010) in combination with 5-FU/LV and oxaliplatin (FOLFOX).

Authors: Hecht, J R Naing, A Falchook, G S et al.

Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p. 1 Chart.

The prognostic significance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials.

Authors: Said, R. Banchs, J. Wheler, J. et al.

Source: Annals of Oncology. Jan2014, Vol. 25 Issue 1, p276-282. 7p.

Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs.

Authors: Naing, A. Veasey-Rodrigues, H. Hong, D. S. et al.

Source: Annals of Oncology. Nov2012, Vol. 23 Issue 11, p2960-2963. 4p. 3 Charts.

Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience.

Authors: Wheler, J. J. Tsimberidou, A. M. Hong, D. S. et al.

Source: Annals of Oncology. Aug2012, Vol. 23 Issue 8, p1963-1967. 5p. 1 Chart, 1 Graph.

Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response.

Authors: Liu, X George, G C Tsimberidou, A M et al.

Source: BMC Cancer. 2015, Vol. 15 Issue 1, p713-713. 1p.

67PPooled safety analysis of tepotinib in Asian patients with advanced solid tumours.

Authors: Yamazaki, K Ryoo, B-Y Doi, T et al.

Source: Annals of Oncology. 2019 Supplement, Vol. 30, pN.PAG-N.PAG. 1p.

75PCemiplimab, a human PD-1 monoclonal antibody, in patients (pts) with recurrent or metastatic cervical cancer: Interim data from phase I cohorts.

Authors: Rischin, D Gil-Martin, M González-Martin, A et al.

Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.

1146PDurability of clinical benefit in metastatic epithelial ovarian cancer patients treated with pegilodecakin monotherapy or in combination with platinum plus taxane-based chemotherapy.

Authors: Autio, K A Naing, A Hung, A et al.

Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p. 1 Chart.